Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 3/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | GUCY1A1 | Q02108 | 5/20 | 0.32 |
| ▸ | GUCY1B1 | Q02153 | 5/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | BUB1 | O43683 | 2/20 | 0.32 |
| ▸ | SYK | P43405 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24205974 | 0.95 | PDE5A (0.40) | PDE5AGRIN1GRIN2BGRM2GUCY1A1 | |
| SCHEMBL20161087 | 0.89 | PDE5A (0.38) | PDE5AGRIN1GRIN2BGUCY1A1GUCY1B1 | |
| SCHEMBL24205854 | 0.87 | PDE5A (0.37) | PDE5AGRIN1GRIN2BGUCY1A1GUCY1B1 | |
| SCHEMBL24205968 | 0.80 | PDE5A (0.38) | PDE5AGUCY1A1GUCY1B1ADORA2ABUB1 | |
| SCHEMBL20161098 | 0.78 | PDE5A (0.35) | PDE5AGRIN1GRIN2BGRM2GUCY1A1 | |
| SCHEMBL20140411 | 0.76 | L3MBTL1 (0.46) | PDE5A | |
| SCHEMBL21787286 | 0.76 | RORC (0.33) | PDE5AGRIN1GRIN2B | |
| SCHEMBL20161090 | 0.74 | PDE5A (0.39) | PDE5AGRIN1GRIN2BGUCY1A1GUCY1B1 | |
| SCHEMBL21787192 | 0.74 | ESR1 (0.46) | PDE5AGRIN1GRIN2BMEN1KMT2A | |
| SCHEMBL20139770 | 0.74 | PDE5A (0.37) | PDE5AGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017515-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| US-11180493-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200071318-A1 | SGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2020-03-05 | — | — | US | disclosed |
| WO-2018089330-A2 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071318-A1 | SGC STIMULATORS | GUCY1A2, GMPS, PDE2A | PDE5A 12/4885GRIN1 1566/4885GRIN2B 1470/4885 |
| US-20220017515-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, PDE2A | PDE5A 12/4885GRIN1 1488/4885GRIN2B 1483/4885 |
| US-11180493-B2 | SGC stimulators | GUCY1A2, GMPS, PDE2A | PDE5A 12/4885GRIN1 1566/4885GRIN2B 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.